Table S2: Characteristics and evolution of patients included in ISRCTN45828668 (A) Demographics. (B) Progression free survival (PFS), adverse events (AE) according to the CTCAE v3.0, further salvage treatments and overall survival after incorporation in the study.

Legend: KPS= Karnofsky performance score; U= unmethylated, M= methylated, NA= unknown; S= Surgery, XRT= radiation therapy, TMZ= Temozolomide, BCNU= Carmustine, PCV= Procarbazine, Lomustine and Vincristine.